All In Biotech

NDA 017530 · Ph Health

Tigan

Trimethobenzamide Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Apr 18, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Jul 12, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

0 Phase 3, 1 recruiting

FAERS reports

1,417

494 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2026.

Indications Tigan ® is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 12, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • TIGAN · TRIMETHOBENZAMIDE HYDROCHLORIDE 100MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Trimethobenzamide" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea332
  • somnolence228
  • dizziness166
  • vomiting132
  • yawning121
  • drug ineffective102
  • blood pressure decreased101
  • fatigue93
  • fall78
  • blood pressure increased68
  • feeling abnormal66
  • drug hypersensitivity62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200424
200528
200630
200744
200830
200927
201032
201141
201251
201334
201422
201545
201681
2017161
2018214
2019183
2020181
2021127
202231
202312
202411
20251
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tigan* (Trimethobenzamide HCl)

2024 spending

$196K

Beneficiaries

173

291 claims

Per beneficiary

$1,132

$25.99 per unit

View as table
YearSpending
2020$193,861
2021$212,624
2022$240,518
2023$161,926
2024$195,915

Part B: Tigan (Trimethobenzamide HCL) · HCPCS J3250

2024 spending

$29K

Beneficiaries

339

649 claims

Per beneficiary

$84

2024 ASP limit $49.00 per unit

View as table
YearSpending
2020$92,686
2021$104,376
2022$90,028
2023$58,558
2024$28,584

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.